ADAADi decreases lipid biosynthesis in breast cancer cells (28) and also sensitizes cells to chemotherapy drugs, just as BRG1 knockdown does (85). After pretreatment with ADAADi, cells were exposed to different doses of six clinically used chemotherapy drugs and cell viability was assayed by MTT. ADAADi significantly increased the drug killing efficacy in MDA-MB-231 and MDA-MB-468 cells from 3-fold to over 10-fold. Therefore, chemical inhibition of the BRG1 ATPase domain targets BRG1-mediated pro-survival pathways in breast cancer cells, decreasing levels of the ABC transporters that pump chemotherapy drugs out of cells and contribute to treatment failure (85).
